Forward Pharma A/S (FWP) Downgraded to “Sell” at ValuEngine
ValuEngine cut shares of Forward Pharma A/S (NASDAQ:FWP) from a hold rating to a sell rating in a research report released on Tuesday morning.
Separately, BidaskClub raised shares of Forward Pharma A/S from a sell rating to a hold rating in a research note on Tuesday, June 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $24.00.
Forward Pharma A/S (NASDAQ FWP) opened at 6.99 on Tuesday. The firm’s market cap is $329.81 million. Forward Pharma A/S has a one year low of $5.46 and a one year high of $33.00. The stock’s 50 day moving average is $24.86 and its 200 day moving average is $22.69.
ILLEGAL ACTIVITY WARNING: “Forward Pharma A/S (FWP) Downgraded to “Sell” at ValuEngine” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/09/13/forward-pharma-as-fwp-downgraded-to-sell-at-valuengine.html.
The firm also recently disclosed an annual dividend, which was paid on Monday, September 11th. Investors of record on Thursday, September 7th were paid a dividend of $22.903 per share. The ex-dividend date of this dividend was Wednesday, September 6th.
Large investors have recently bought and sold shares of the stock. Baupost Group LLC MA boosted its stake in Forward Pharma A/S by 3.9% during the first quarter. Baupost Group LLC MA now owns 5,575,407 shares of the biotechnology company’s stock worth $119,927,000 after acquiring an additional 208,107 shares in the last quarter. Eqis Capital Management Inc. boosted its stake in Forward Pharma A/S by 25.5% during the second quarter. Eqis Capital Management Inc. now owns 20,178 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 4,097 shares in the last quarter. Alps Advisors Inc. bought a new stake in Forward Pharma A/S during the second quarter worth about $866,000. Citadel Advisors LLC bought a new stake in Forward Pharma A/S during the first quarter worth about $269,000. Finally, Marshall Wace North America L.P. bought a new stake in Forward Pharma A/S during the first quarter worth about $612,000. 21.85% of the stock is currently owned by institutional investors and hedge funds.
Forward Pharma A/S Company Profile
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Stock Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related stocks with our FREE daily email newsletter.